PCSK9 and homozygous familial hypercholesterolemia: Other novel lipid-lowering agents, including lomitapide [14,15], mipomersen [16,17], PCSK9 inhibitors (e.g., alirocumab, evolocumab, and inclisiran) [18,19,20,21,22,23], and evinacumab [24,25], have been shown to significantly reduce LDL-C levels in adult HoFH patients.